

Workshop 3: RADAR Remote Assessment of Diseases And Relapse

Prof T F Meert, PhD., PhD.

Senior Director External Innovation, Discovery Sciences

Universities: KUL, UA, UH, UG, VUB

Nationalen Informationsveranstaltung zur Innovative Medicines Initiative (IMI2)

DECHEMA-Haus, Frankfurt am Main, Germany, July 10th, 2014





Introduction



- Remote Assessment for Disease and Relapse (RADAR) is a candidate project as part of the IMI2 joint undertaking
- The EFPIA research directors group have endorsed the RADAR co-ordinators to explore the interest from other companies to participate in this project
- This presentation provides an straw man proposal for the RADAR project for discussion among (EFPIA) partners

Remote Assessment of Diseases And Relapse (RADAR)



Overall objective

The overall objective of the RADAR project is to develop and validate the science and regulatory approach of using a remote assessment approach to derive biosignatures that characterise disease and predict changes in disease state to support the pre-emption of treatment

To deliver on this objective, we anticipate the following deliverables:

- The prosecution of a series of observational studies in different therapeutic areas to assess the utility of remote assessment technology in a) characterizing disease and disease fluctuations and b) feasibility and patient compliance
- The development of novel biosensor technology that both remotely and passively measures physiological and behavioral endpoints
- An improved understanding of the regulatory pathways for using remote assessment in healthcare
- 4. The development and publishing of standards for Information Exchange that enable seamless integration of sensor, data capture, data management, & analysis technologies
- The development of an open source reference platform to enable the collection storage and analysis of remote assessment data

We clearly need to ∆ the Paradigm from Diagnose & Treat to Predict & Preempt: many challenges......





 Need to be able to quantitate physiological/pathophysiological parameters, and intervene before transitions into more severe disease states

Clinic visits are **time-limited evaluations** based on **subjective observations** of both the patient and the HCP



Changes in disease state for each of these diseases can occur on timescales much shorter than the interval between clinic visits

Through technological advances over the last decade it is now possible to **objectively**, **remotely**, **and continuously** measure aspects of patient **physiology**, **behavior and symptoms**












Emerging Technology for Continuous Patient Assessment



Physiology



ECG
HR/HRV
Respiration
Skin temp
Activity/Sleep
O2 sat



Behavior

GPS

Talk patterns
Text patterns
Activity/Sleep



IVR

Smartphone Symptom assessment



Escalating Data Challenge:

How the types of data we collect is evolving.....









Discrete Decentralized

Non-Discrete Decentralized

Proint—of-Facility'
 Discrete, Structured,
 Information Events
 Controlled
 Populations
 (clinical trials,
 longitudinal

disease studies)

≻'Point-of-Need'
 ➤ Real-Time Multiplexed Read-Outs
 (Diagnostic, Prognostic, Drug Monitoring)
 ➤ Distributed Populations in Clinic Settings

➤ Semi-Continuous➤ Semi-Structureddata➤ Multiple sources

....So Data is Evolving to Continuous Streams of Information

'Quantified Self'





Social Media

New DataTypes
New Tools for:
Information extraction,
Knowledge representation
Integration, Data Mining



Mobile Computing Devices






Remote Monitoring Sensors

On-Patient

- Actigraphy
- Speech
- Eye movement
- EKG, HR, HRV
- EEG
- Sleep
- Galvanic skin response
- 02 Sat
- Skin temperature

Off-Patient

- Fixed cameras
- Bed embedded sensors
- Computer usage
- Phone usage
- Refrigerator usage
- Motion sensors



As we derive signatures of disease/relapse from the new continuous data types, we don't have to start from scratch




EWSQ 10 Patient Version	Potential Technology Correlates
Has your sleep worsened since the last evaluation?	Sleep EEG Actigraphy
Has your appetite decreased since the last evaluation?	
Has your concentration, e.g., ability to read or watch TV, worsened since the last evaluation?	Eye tracking Computer tracking
Have you experienced fear, suspiciousness, or other uneasy feelings while being around people since the last evaluation?	Skin Conductance Heart rate / variability
Have you experienced increased restlessness, agitation, or irritability since the last evaluation?	Actigraphy Galvanic Skin Response Speech Analysis
Have you noticed that something unusual or strange is happening around you since the last evaluation?	
Have you experienced loss of energy or interest since the last evaluation?	Actigraphy Cell phone location
Has your capability to cope with everyday problems worsened since the last evaluation?	
Have you experience the aring other new every mobody was around since	

Have you notice

these technologies use prior clinical knowledge, as well as the <u>known history</u> of the patients

Case Study I: Brain Health Registry Digital, Distributed Longitudinal Assessment of Cognition




Case Study II: Remote assessment of maintenance of treatment response in MDD patients


- a. Identify patients who may be at increased risk of near term relapse
- b. Enable measurement-based changes to maintenance regimen

STAR-D: Subjects w/ greater number of residual symptoms after remission of MDD had a greater probability of relapse

Nierenberg et al., 2010



Few studies have addressed predictors of near term relapse or onset of relapse prodrome in MDD



RADAR Workshop

Kick-starting a coalition on Remote Assessment of Disease and Relapse Workshop 23-05-2014







Dear Sir/Madam,

We would like to kindly invite you to join the Innovative Medicines Initiative – RADAR Workshop - Kick-starting a coalition on Remote Assessment for Disease and Relapse - which will be held on 23 May 2014, Brussels.

Venue:

Stanhope Hotel Rue du Commerce 9 B-1000 Brussels

Radar kick-off meeting



Kick-starting a coalition on Remote Assessment of Disease and Relapse *Workshop 23-05-2014*



RADAR is a candidate project as part of the IMI2 joint undertaking

Remote Assessment of Diseases And Relapse (RADAR) - AIMS



- Develop and validate the science of using biosignatures to characterise disease and predict changes in disease state through observational studies
- Encourage innovation and development of novel biosensors and the associated knowledge management technology
- Understand the regulatory pathways for using remote assessment in healthcare
- Develop standards for Information Exchange that enable seamless integration of sensor, data capture, data management, & analysis technologies

Why a Public Private Partnership is needed



AIM	PPP Requirement
Develop and validate the science of using biosignatures to characterise disease and predict changes in disease state	Requires input from EFPIA, Academia {Medical Sciences, Engineering, Infomatics}, Patient Groups for success
Encourage innovation and development of novel biosensors and the associated knowledge management technology	Requires a vibrant eco system of innovative sensor providers from both Academic and SME environment
Understand the regulatory pathways for using remote assessment in healthcare	Needs input from EFPIA and Regulators to understand the regulatory requirement of using such technology
Develop standards for Information Exchange that enable seamless integration of sensor, data capture, data management, & analysis technologies	Requires participation from Industry, Academia, SME, and Large Technology companies to provide technology that can integrate

Skills and Knowhow



Contributions from EFPIA

- Clinical Trial Design and Operation
- Disease Understanding from prior clinical trial
- Preliminary Know-how about use of remote sensing in clinical trials
- Data Management and Informatics

Contributions from Applicants

 Clinical Investigators, Biosensors Data Management and Informatics, Regulators, Patient Groups

Opportunities from SME

 This project offers a clear role for SMEs in the development in unique biosensor technology

Next Steps RADAR




- 5 Disease-area related follow-up working groups
 - CV/Metabolic
 - Diabetes
 - CNS (mood, pain)
 - Respiratory (Asthma and COPD)
 - Autoimmune (RA, MS)
- One overarching technology working group
- One work stream directed to legal aspects, patient engagement



New workshop planned: September 2nd

RADAR- Vision









Example: Technology Correlates to Clinical Parameters



EWSQ 10 Patient Version	Potential Technology Correlates
Has your sleep worsened since the last evaluation?	Sleep EEG (iVigil) Actigraphy (Hidalgo)
Has your appetite decreased since the last evaluation?	
Has your concentration, e.g., ability to read or watch TV, worsened since the last evaluation?	Eye tracking (Monarca)
Have you experienced fear, suspiciousness, or other uneasy feelings while being around people since the last evaluation?	Skin Conductance (Hidalgo) Heart rate / variability (Hidalgo) Cell phone location (Monarca)
Have you experienced increased restlessness, agitation, or irritability since the last evaluation?	Actigraphy (Hidalgo) Galvanic Skin Response (Hidalgo) Speech Analysis (Hidalgo/IBM)
Have you noticed that something unusual or strange is happening around you since the last evaluation?	
Have you experienced loss of energy or interest since the last evaluation?	Actigraphy (Hidalgo) Computer Tracking (Monarca)
Has your capability to cope with everyday problems worsened since the last evaluation?	Speech Analytics (Hidalgo/IBM)
Have you experienced hearing other people's voices even when nobody was around since the last evaluation?	
Have you noticed any other of your individual early warnings signs since the last evaluation?	